Healthcare Growth Division of EQT to Acquire Europa Biosciences
**EQT Healthcare Growth Acquires Europa Biosite to Boost Life Sciences Distribution**
In a move aimed at bolstering its presence in the distribution of life science reagents and biological substances, EQT Healthcare Growth has announced the acquisition of Europa Biosite. The deal marks a strategic step for EQT Healthcare Growth, as it seeks to expand its commercial capabilities and geographic reach in the industry.
Europa Biosite, a leading distributor of high-quality research-use-only (RUO) life science reagents, chemicals, and biological substances, serves over 60,000 academic and biopharma researchers across 17 countries in Europe and North America. The company offers access to more than ten million scientific products that are essential for life sciences research, including antibodies, biochemicals, diagnostic kits, and ethically sourced biospecimens.
Rikke Kjær Nielsen, Partner in the EQT Healthcare Growth advisory team, expressed her excitement about the partnership, stating, "Europa Biosite is a company that enables critical research, and we are proud to support its growth and development."
EQT Healthcare Growth plans to support Europa Biosite's growth through investments into digital tools, strengthening of its supplier network, and acceleration of its M&A platform. Sune Schmølker, who will be the Chairperson of Europa Biosite, believes that the partnership will provide an opportunity for Europa Biosite to grow and contribute to the development of the life sciences sector. Schmølker, previously the Chairperson of Beijer Ref, another Swedish specialised distribution business, brings valuable experience in scaling businesses to the table.
Senior EQT advisor Kate Swann will lead Europa Biosite's Board, guiding the company's strategic growth. Swann's expertise in specialised distribution is expected to be beneficial for Europa Biosite, as it seeks to expand its biospecimen offerings, strengthen its local market presence, enter new regions, and invest in digital infrastructure.
The growing demand for reagents is seen as a pivotal moment for Europa Biosite's business, and EQT's expertise in scaling distributors is expected to be instrumental in capitalising on this opportunity. The partnership between Europa Biosite and EQT Healthcare Growth aims to reach new customers, offer better service, and bring new products to market.
The acquisition represents a significant step towards consolidation and increased specialization in a largely fragmented market. The deal is expected to facilitate greater access to advanced research products, strengthen supplier and scientist partnerships, and sustain market growth dynamics driven by stable research funding and continued demand for advanced life science research tools.
The potential ripple effects could encourage further M&A activity and digital transformation in the distribution ecosystem, raising industry standards and efficiencies. Europa Biosite, with its extensive product portfolio and global reach, is well-positioned to lead these changes, contributing to the advancement of healthcare and biopharma innovation.
- EQT Healthcare Growth, in its pursuit of expanding its business, plans to support Europa Biosite's growth through investments in areas such as digital tools and strengthening of its supplier network, with a focus on investing in digital infrastructure and accelerating its M&A platform.
- As EQT Healthcare Growth seeks to strengthen its presence in the distribution of life science reagents and biological substances, the acquisition of Europa Biosite, a leading distributor of research-use-only life science reagents, chemicals, and biological substances, represents a strategic step in finance and investing for the growth-oriented fund.
